First-in-Human Study of BGB-45035 in Healthy Adults and Autoimmune Patients
The first-in-human study of BGB-45035 will assess its safety and pharmacokinetics in healthy participants and adults with autoimmune dermatological diseases.
Asset / Drug
Drug and asset intelligence for BGB-45035 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.